ADDA members, please pat yourselves on the back. You deserve it.
In the spring of 2012, ADDA’s Public Policy Committee opened the ADDA Legislative Center on our Web site. The Legislative Center provides a central location ADDA members can stay up to date on proposed laws and government initiatives that are important to adults with ADHD and their loved ones, and is an essential advocacy tool for any organization wishing to influence government on behalf of its members. The FDA Safety and Innovation Act is the first bill for which ADDA sent an alert to its members, and it has now become law of the land!
Imagine how thrilled we were when we learned…
President Obama signs legislation that includes Congressman Carney's proposal to reduce drug shortages
President Obama today signed the FDA Safety and Innovation Act, which includes important components of Congressman Carney’s Drug Shortage Prevention Act. Last month, the House of Representatives and the Senate passed the legislation with broad bipartisan support.
"Today’s developments are encouraging for all of the patients across America who are not getting the treatments they need because of preventable drug shortages,” said Congressman Carney. "The provisions from the Drug Shortage Prevention Act will ensure that more critical drugs are produced by manufacturers and reach the patients who need them. I thank my House and Senate colleagues for their support, and I'm glad that President Obama has signed this important legislation into law.”
A number of key provisions from Congressman Carney’s drug shortage prevention bill are included in the FDA legislation, including:
· Creation of a publically available Drug Shortage List with information about the reason for the shortage and estimated date by which drugs will begin reaching providers in a quantity sufficient to meet demand.
· Expedited review of any application seeking approval of a critical drug and any request by a manufacturer of a critical drug to approve a change to the manufacturing process or facilities of that drug in order to mitigate or prevent a shortage.
· Improved regulation of critical drugs to ensure that, at each stage of the regulatory process, the status of drugs as critical drugs is taken into consideration.
· Development of improved communications between offices within FDA responsible for approving and regulating critical drugs and offices of FDA responsible for identifying and addressing critical drug shortages.
· If a drug on the critical drug shortage list pertains to a controlled substance subject to a quota, the Attorney General is directed to increase the quota, in consultation with the Secretary of Health and Human Services, to address the critical drug shortage.
One hundred and nineteen ADDA members supported the alert sent to our subscribers; they contacted their own representatives in Congress via ADDA's Legislative Center and ADDA membership support was key in getting this passed by the House. In a time when even a few constituents taking the time to make their feelings known to their government representatives by writing or calling, our ADDA members offered a "landslide” of support.
Once again, congratulations. We are now "movers and shakers,” and we really are "helping adults with ADHD lead better lives.
The Attention Deficit Disorder Association (ADDA) is a nonprofit organization established in 1989 to provide information, resources and networking to adults with AD/ HD and to the professionals who work with them. In doing so, ADDA generates hope, awareness, empowerment and connections worldwide in the field of AD/HD. Bringing together scientific perspectives and the human experience, the information and resources provided to individuals and families affected by AD/HD and professionals in the field focuses on diagnoses, treatments, strategies and techniques for helping adults with AD/ HD lead better lives. For more information visit: www.add.org.